Control trials and statistical analysis were carried out to assess the effects of albumin‐collodion microencapsulated activated charcoal (ACAC) hemoperfusion on fulminant hepatic coma. A rat model of galactosamine induced fulminant hepatic coma was used. Rats which did not recover died at 3.0 0.6 days after galactosamine injection. Those which survived this period recovered. Forty‐eight hours after galactosamine injection, a test group of 21 rats were treated with 1 hour hemoperfusion and compared with an untreated group of 23 rats. 71.4% of the treated group survived as compared to 30.4% of the untreated rats. Statistical analysis (t test) shows a significant increase in recovery for the treated group (<0.01). Biochemical and histological results will be discussed.

No abstract

No abstract

No abstract

No abstract